Provectus Biopharmaceuticals to Meet with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Study with Aim to Maximize Speed
December 22, 2014 at 06:01 AM EST
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, http://www.pvct.com ), a development-stage oncology and dermatology biopharmaceutical ...